Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation

Biotech Giants' SG&A Costs: A Decade of Growth

__timestampDynavax Technologies CorporationVericel Corporation
Wednesday, January 1, 20141776300013774000
Thursday, January 1, 20152218000022479000
Friday, January 1, 20163725700027388000
Sunday, January 1, 20172736700035610000
Monday, January 1, 20186477000049007000
Tuesday, January 1, 20197498600061139000
Wednesday, January 1, 20207925600068836000
Friday, January 1, 202110015600097592000
Saturday, January 1, 2022131408000106903000
Sunday, January 1, 2023152946000120998000
Loading chart...

Data in motion

A Decade of SG&A Expenses: Vericel vs. Dynavax

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Vericel Corporation and Dynavax Technologies Corporation have shown significant shifts in their Selling, General, and Administrative (SG&A) expenses. Dynavax, with a 760% increase, saw its SG&A costs rise from approximately $18 million in 2014 to $153 million in 2023. Meanwhile, Vericel's expenses grew by 780%, from $14 million to $121 million in the same period.

Key Insights

  • 2014-2018: Both companies maintained a steady growth trajectory, with Vericel slightly trailing Dynavax.
  • 2019-2023: A notable surge in expenses, reflecting strategic expansions and increased operational activities.

These trends highlight the dynamic nature of the biotech sector, where strategic investments in administration and sales are pivotal for growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025